Table 2.
Incidence of severe CIT (CTCAE grade 3–4) in typical chemotherapy regimens and cancer types [9]
| Incidence of Grade 3 CIT (%) | Incidence of Grade 4 CIT (%) | |
|---|---|---|
| Chemotherapy regimen | ||
| Gemcitabine | 5.5 | 2.5 |
| Platinum | 4.3 | 2.1 |
| Anthracycline | 7.1 | 3.6 |
| Taxane | 2.0 | 0.8 |
| Other | 10.2 | 7.2 |
| Cancer type | ||
| Lung | 5.1 | 2.6 |
| Colon or rectum | 4.3 | 1.7 |
| Breast | 2.7 | 0.9 |
| Pancreas | 4.0 | 1.4 |
| Head or neck | 2.6 | 0.7 |
| Ovary | 4.3 | 2.1 |
| Prostate | 4.5 | 1.9 |
| Bladder | 5.9 | 3.6 |
| Uterine | 4.3 | 4.0 |
| Melanoma | 13.3 | 5.0 |
| Non-Hodgkin Lymphoma | 13.2 | 9.1 |
| Multiple Myeloma | 23.5 | 18.8 |
| Hodgkin Lymphoma | 3.6 | 2.8 |
| Leukemia and myelodysplastic syndromes | 16.3 | 14.3 |